On Feb. 14, the U.S. Food and Drug Administration notified healthcare professionals and patients about a counterfeit version of Avastin 400 mg/16mL, which may have been purchased and used by some medical practices in the United State. The counterfeit version of Avastin does not contain the medicine’s active ingredient, bevacizumab. Read more.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
